{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:15:04Z","timestamp":1790936104242,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T00:00:00Z","timestamp":1254182400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1038\/sj.bjc.6605241","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T22:51:08Z","timestamp":1254264668000},"page":"1051-1058","source":"Crossref","is-referenced-by-count":71,"title":["Atacicept in relapsed\/refractory multiple myeloma or active Waldenstr\u00f6m's macroglobulinemia: a phase I study"],"prefix":"10.1038","volume":"101","author":[{"given":"J-F","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Requirand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Rouill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Nestorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Mordenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ythier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,29]]},"reference":[{"key":"BF6605241_CR1","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/sj.leu.2404228","volume":"20","author":"M Abe","year":"2006","unstructured":"Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H, Matsumoto T (2006) BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 20: 1313\u20131315","journal-title":"Leukemia"},{"key":"BF6605241_CR2","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1073\/pnas.0800555105","volume":"105","author":"A Ahuja","year":"2008","unstructured":"Ahuja A, Anderson SM, Khalil A, Shlomchik MJ (2008) Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci USA 105: 4802\u20134807","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF6605241_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1158\/1078-0432.CCR-07-4435","volume":"14","author":"SM Ansell","year":"2008","unstructured":"Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, Nestorov I, Devries T, Dillon SR, Hausman D, Novak AJ (2008) Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 14: 1105\u20131110","journal-title":"Clin Cancer Res"},{"key":"BF6605241_CR4","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","volume":"180","author":"MJ Benson","year":"2008","unstructured":"Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, Noelle RJ (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180: 3655\u20133659","journal-title":"J Immunol"},{"key":"BF6605241_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2141.1994.tb04986.x","volume":"88","author":"J Blad\u00e9","year":"1994","unstructured":"Blad\u00e9 J, Lopez-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C (1994) Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haemat 88: 117\u2013121","journal-title":"Br J Haemat"},{"key":"BF6605241_CR6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haemat 102: 1115\u20131123","journal-title":"Br J Haemat"},{"key":"BF6605241_CR7","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O\u2032Brien S, Rai KR (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990\u20134997","journal-title":"Blood"},{"key":"BF6605241_CR8","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244","journal-title":"J Clin Oncol"},{"key":"BF6605241_CR9","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1002\/art.23047","volume":"56","author":"M Dall\u2019Era","year":"2007","unstructured":"Dall\u2019Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56: 4142\u20134150","journal-title":"Arthritis Rheum"},{"key":"BF6605241_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","volume":"27","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, Fermand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP (2009) Update on treatment recommendations from the Fourth International Workshop on Waldenstr\u00f6m's Macroglobulinemia. J Clin Oncol 27: 120\u2013126","journal-title":"J Clin Oncol"},{"key":"BF6605241_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1200\/JCO.2000.18.1.214","volume":"18","author":"MA Dimopoulos","year":"2000","unstructured":"Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M (2000) Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 18: 214\u2013226","journal-title":"J Clin Oncol"},{"key":"BF6605241_CR12","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2005-09-3552","volume":"107","author":"SF Elsawa","year":"2006","unstructured":"Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, Dillon SR, Harder B, Gross JA, Ansell SM (2006) B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 107: 2882\u20132888","journal-title":"Blood"},{"key":"BF6605241_CR13","volume-title":"GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide","author":"J Ferlay","year":"2004","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARCPress: Lyon"},{"key":"BF6605241_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/intimm\/7.7.1093","volume":"7","author":"MP Gras","year":"1995","unstructured":"Gras MP, Laabi Y, Linares-Cruz G, Blondel MO, Rigaut JP, Brouet JC, Leca G, Haguenauer-Tsapis R, Tsapis A (1995) BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol 7: 1093\u20131106","journal-title":"Int Immunol"},{"key":"BF6605241_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/35010115","volume":"404","author":"JA Gross","year":"2000","unstructured":"Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995\u2013999","journal-title":"Nature"},{"key":"BF6605241_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","volume":"15","author":"JA Gross","year":"2001","unstructured":"Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15: 289\u2013302","journal-title":"Immunity"},{"key":"BF6605241_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.6004\/jnccn.2007.0016","volume":"5","author":"JL Harousseau","year":"2007","unstructured":"Harousseau JL, Moreau P (2007) Role of bone marrow transplantation in the disease pathway of myeloma. J Natl Compr Canc Netw 5: 163\u2013169","journal-title":"J Natl Compr Canc Netw"},{"key":"BF6605241_CR18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.cdd.4401647","volume":"12","author":"J Hendriks","year":"2005","unstructured":"Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, Medema JP (2005) Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 12: 637\u2013648","journal-title":"Cell Death Differ"},{"key":"BF6605241_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.0105-2896.2006.00380.x","volume":"211","author":"T Hofer","year":"2006","unstructured":"Hofer T, Muehlinghaus G, Moser K, Yoshida T, E Mei H, Hebel K, Hauser A, Hoyer B, E OL, Dorner T, Manz RA, Hiepe F, Radbruch A (2006) Adaptation of humoral memory. Immunol Rev 211: 295\u2013302","journal-title":"Immunol Rev"},{"key":"BF6605241_CR20","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1084\/jem.20042309","volume":"201","author":"K Ingold","year":"2005","unstructured":"Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, Rennert PD, Tschopp J, Schneider P (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201: 1375\u20131383","journal-title":"J Exp Med"},{"key":"BF6605241_CR21","first-page":"335","volume":"246","author":"B Klein","year":"1999","unstructured":"Klein B, Li XY, Lu ZY, Jourdan M, Tarte K, Brochier J, Claret E, Wijdenes J, Rossi JF (1999) Activation molecules on human myeloma cells. Curr Top Microbiol Immunol 246: 335\u2013341","journal-title":"Curr Top Microbiol Immunol"},{"key":"BF6605241_CR22","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1182\/blood-2006-08-043232","volume":"109","author":"K Mahtouk","year":"2007","unstructured":"Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, Moehler T, Rossi JF, R\u00e8me T, Goldschmidt H, Klein B (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109: 4914\u20134923","journal-title":"Blood"},{"key":"BF6605241_CR23","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"J Moreaux","year":"2004","unstructured":"Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103: 3148\u20133157","journal-title":"Blood"},{"key":"BF6605241_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","volume":"106","author":"J Moreaux","year":"2005","unstructured":"Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, Rossi JF, Hose D, Klein B (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106: 1021\u20131023","journal-title":"Blood"},{"key":"BF6605241_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.10574","volume":"92","author":"J Moreaux","year":"2007","unstructured":"Moreaux J, Hose D, Jourdan M, Reme T, Hundemer M, Moos M, Robert N, Moine P, De Vos J, Goldschmidt H, Klein B (2007) TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 92: 803\u2013811","journal-title":"Haematologica"},{"key":"BF6605241_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","volume":"83","author":"J Moreaux","year":"2009","unstructured":"Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, Moine P, Robert N, Jourdan E, Rossi JF, Klein B (2009) APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 83: 119\u2013129","journal-title":"Eur J Haematol"},{"key":"BF6605241_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00228-007-0311-7","volume":"63","author":"A Munafo","year":"2007","unstructured":"Munafo A, Priestley A, Nestorov I, Visich J, Rogge M (2007) Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 63: 647\u2013656","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6605241_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103: 689\u2013694","journal-title":"Blood"},{"key":"BF6605241_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2032Connor","year":"2004","unstructured":"O\u2032Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199: 91\u201398","journal-title":"J Exp Med"},{"key":"BF6605241_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1172\/JCI26385","volume":"116","author":"M Ramanujam","year":"2006","unstructured":"Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, Frank D, Rice J, Diamond B, Yu KO, Porcelli S, Davidson A (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116: 724\u2013734","journal-title":"J Clin Invest"},{"key":"BF6605241_CR31","first-page":"2566","volume":"106","author":"J-F Rossi","year":"2005","unstructured":"Rossi J-F, Moreaux J, Rose M, Picard M, Ythier A, Rossier C, Sievers E, Klein BA (2005) Phase I\/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated Waldenstrom's macroglobulinemia (WM). Blood (ASH Annual Meeting Abstracts) 106: 2566","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BF6605241_CR32","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747\u20131756","journal-title":"J Exp Med"},{"key":"BF6605241_CR33","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","volume":"66","author":"YT Tai","year":"2006","unstructured":"Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66: 6675\u20136682","journal-title":"Cancer Res"},{"key":"BF6605241_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.23178","volume":"58","author":"P Tak","year":"2008","unstructured":"Tak P, Thurlings R, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A (2008) Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis and Rheum 58: 61\u201372","journal-title":"Arthritis and Rheum"},{"key":"BF6605241_CR35","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1126\/science.1061965","volume":"293","author":"JS Thompson","year":"2001","unstructured":"Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108\u20132111","journal-title":"Science"},{"key":"BF6605241_CR36","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","volume":"15","author":"SP Treon","year":"2004","unstructured":"Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC (2004) Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstr\u00f6m's macroglobulinemia. Ann Oncol 15: 1481\u20131483","journal-title":"Ann Oncol"},{"key":"BF6605241_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3816\/CLM.2009.n.001","volume":"9","author":"SP Treon","year":"2009","unstructured":"Treon SP, Patterson CJ, Kimby E, Stone MJ (2009) Advances in the biology and treatment of Waldenstr\u00f6m's macroglobulinemia: a report from the 5th International Workshop on Waldenstr\u00f6m's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma 9: 10\u201315","journal-title":"Clin Lymphoma Myeloma"},{"key":"BF6605241_CR38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.critrevonc.2008.03.008","volume":"67","author":"U Vitolo","year":"2008","unstructured":"Vitolo U, Ferreri AJ, Montoto S (2008) Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Crit Rev Oncol Hematol 67: 172\u2013185","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF6605241_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1126\/science.278.5335.138","volume":"278","author":"GU Von Bulow","year":"1997","unstructured":"Von Bulow GU, Bram RJ (1997) NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278: 138\u2013141","journal-title":"Science"},{"key":"BF6605241_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.leu.2405048","volume":"22","author":"S Yaccoby","year":"2008","unstructured":"Yaccoby S, Pennisi A, Li XY, Dillon SR, Zhan F, Barlogie B, Shaughnessy JDJ (2008) Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22: 406\u2013413","journal-title":"Leukemia"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605241","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:41:24Z","timestamp":1684413684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,29]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["BF6605241"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605241","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,29]]}}}